Trade Therapy

Page 68

52

Trade Therapy: Deepening Cooperation to Strengthen Pandemic Defenses

quickly enough. Accelerating their arrival by one, two, or three months could have saved an estimated hundreds of thousands of lives and trillions of dollars of economic activity (Athey et al. 2022). Also, the distribution of COVID-19 vaccines was skewed toward the regions where doses were manufactured (as noted earlier), which is why many have called for efforts to diversify vaccine manufacturing capacity globally to better prepare for future health emergencies. Furthermore, the scale of production was too small. The lack of sharing meant that less than 10 percent of the population in poor countries were inoculated by the end of 2021. New demand for boosters along with waste of unused and expired doses pushed the overall need for capacity far above 11.5 billion doses. Getting a new vaccine from beginning to end requires investment in sizable sunk costs (figure 1.22). These include the scientific research to invent the vaccine; the clinical trials to develop and check that it is effective and safe; the creation of a dedicated Figure 1.22

The vaccine value chains

Vaccine origination and development

1

Research and development

License Vaccine manufacturing formula to

3

Send vaccine formula for testing

Drug substance and drug product formulation Inputs Send drug product to

4

Fill and finish Inputs

2

Cliinical trials

Capital equipment

Raw and single-use materials

• Bioreactors • Pumps • Filtration units

• Bioreactor bags • Cellular material • Filters

Capital equipment

Other inputs

• Vial-filling equipment

Send vaccine doses to

Other pharmaceutical ingredients • Adjuvants • Lipids • Preservatives • Excipients

• Glass vials • Stoppers • Refrigeration

Delivery

5

Distribution

Equipment Inputs

• Needles • Syringes • Diluents • Antiseptic wipes

Source: Bown and Bollyky 2022. ©John Wiley and Sons. Reproduced with permission from John Wiley and Sons; further permission required for reuse. Note: Stages and inputs depicted illustrate the general vaccine production process and are not comprehensive.


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

response for future pandemics

18min
pages 177-187

Notes

11min
pages 165-168

References

12min
pages 169-174

3.2 Low levels of GATS commitments in medical services trade

1min
page 147

commitments than in GATS

15min
pages 148-154

Cooperation beyond trade agreements for global health security

22min
pages 155-164

3.3 Potential commitments to bolster governance of trade policy in global crises

20min
pages 131-139

Trade policy cooperation to contribute to global health security

3min
pages 127-128

3.5 Traceability and illicit trade in medical products in Africa

5min
pages 145-146

B3.4.2 Types of health technology transfer programs reported by WTO developed country members under TRIPS Agreement, art. 66.2, 2018–20

5min
pages 142-144

3.2 Pricing policies for medical goods in the context of international trade

6min
pages 124-126

3.1 RTA cooperation during the COVID-19 pandemic

6min
pages 121-123

References

12min
pages 114-118

Policies affecting medical goods and services trade during the COVID-19 pandemic

2min
page 96

the onset of the COVID-19 pandemic (excluding China), January 2020 to March 2022

5min
pages 108-110

Notes

8min
pages 111-113

2.11 NRA decisions on WHO-EUL COVID-19 vaccines, December 2020 to February 2022

8min
pages 104-107

2.7 Government support measures for the medical goods sector predated the pandemic

6min
pages 93-95

2.4 Trade in medical services faces many trade barriers

5min
pages 88-90

References

8min
pages 71-74

2.2 WTO-notified quantitative restrictions, by type and member income group, 2018–19

3min
pages 80-81

2.3 Progress on implementation commitments under the WTO Trade Facilitation Agreement

10min
pages 82-86

1.22 The vaccine value chains

3min
pages 68-69

2.2 Development of export-oriented medical services in selected countries

2min
page 87

1.17 Exports of PPE soared early in the COVID-19 pandemic

0
page 63

Notes

2min
page 70

1.11 Trade in medical services hit US$78.6 billion in 2019

1min
page 56

1.3 Recent FDI trends in medical goods and services

2min
page 46

Personnel—and the blurred boundaries between trade in medical services and migration of health workers

5min
pages 43-44

1.6 MNCs’ contribution to global value added and exports varies by industry

3min
pages 50-51

Patterns in medical goods and services trade before the pandemic

2min
page 52

B1.1.1 Private health insurance schemes as a share of total health expenditure in selected countries, 2019

3min
pages 41-42

1.1 Access to health care: The role of (trade in) health insurance services

2min
page 40

Drivers of trade in medical goods and services

2min
page 36

of medical goods and services, leading to concentration

8min
pages 32-35

Notes

1min
page 23

1 Trade and trade-related policy actions to improve prevention, preparedness, and

2min
page 20

Deepening cooperation on medical goods and services trade

4min
pages 21-22

Stronger trade systems for better global health security

1min
page 25

References

1min
page 24

Organization of the report

1min
page 26

Reference

0
pages 27-28

The medical goods and services trade: Relevance, characteristics, and welfare implications

1min
page 29
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.